Federal Bureau of Prisons, Safford, AZ, USA.
J Am Pharm Assoc (2003). 2012;52(6):798-801. doi: 10.1331/JAPhA.2012.10208.
To present outcomes resulting from the implementation of a pharmacist-run human immunodeficiency virus (HIV) medication management model.
Federal Bureau of Prisons (BOP) from December 2004 to December 2009.
The BOP instituted the National HIV Clinical Pharmacist Consultant (NHCPC) program in December 2004. NHCPCs monitor and provide guidance as to the appropriateness of antiretroviral therapy (ART) throughout the BOP. They also serve as readily accessible resources for all BOP providers, having the training and expertise necessary to affect positive patient outcomes. NHCPCs were provided intensive training through a Johns Hopkins University HIV/acquired immunodeficiency syndrome pharmacotherapy traineeship administered by the American Society of Consultant Pharmacists and have AAHIVE (HIV Expert) credentialing.
NHCPCs monitor HIV therapy and patient outcomes via BOP electronic medical records.
The vision for this program encompasses an overall healthier BOP HIV patient population being treated in accordance with current Department of Health & Human Services guidelines. Specifically, all patients taking ART have the goals of (1) achieving undetectable viral loads (≥70%), (2) maintaining CD4 T-cell counts of 200 cells/mm3 or more (≥70%), and (3) taking at least 90% of prescribed doses.
From April 2004 to December 2009, the overall percentage of BOP patients with undetectable viral loads increased from 32% to 66%. As of December 2009, 76% of patients receiving ART achieved CD4 counts of 200 cells/mm3 or greater and 73% were taking 90% or more of prescribed doses.
The NHCPC program lends credence to the value of pharmacists in improving patient outcomes.
介绍实施药剂师主导的人类免疫缺陷病毒(HIV)药物管理模式所产生的结果。
联邦监狱局(BOP)于 2004 年 12 月至 2009 年 12 月。
BOP 于 2004 年 12 月启动了国家 HIV 临床药剂师顾问(NHCPC)计划。NHCPC 监测并提供指导,以确保整个 BOP 的抗逆转录病毒治疗(ART)的适当性。他们还作为 BOP 所有提供者随时可获得的资源,具有影响积极的患者结果所需的培训和专业知识。NHCPC 通过美国顾问药剂师协会管理的约翰霍普金斯大学 HIV/获得性免疫缺陷综合征药物治疗研究员培训课程接受了强化培训,并获得 AAHIVE(HIV 专家)认证。
NHCPC 通过 BOP 电子病历监测 HIV 治疗和患者结果。
该计划的愿景是使整体上更健康的 BOP HIV 患者群体按照当前卫生与公众服务部的指南接受治疗。具体而言,所有接受 ART 的患者都有以下目标:(1)实现病毒载量不可检测(≥70%);(2)保持 CD4 T 细胞计数 200 个细胞/mm3 或更高(≥70%);(3)至少服用 90%的规定剂量。
从 2004 年 4 月至 2009 年 12 月,BOP 患者中病毒载量不可检测的总体百分比从 32%增加到 66%。截至 2009 年 12 月,接受 ART 的 76%的患者达到 CD4 计数 200 个细胞/mm3 或更高,73%的患者服用 90%或更多规定剂量。
NHCPC 计划证明了药剂师在改善患者结果方面的价值。